Portal de Periódicos da CAPES

Evasion of host defences by tumours

1987; Wiley; Volume: 65; Issue: 4 Linguagem: Inglês

10.1038/icb.1987.33

1440-1711

D. S. Nelson, Margaret Nelson,

RNA Interference and Gene Delivery

Immunology & Cell BiologyVolume 65, Issue 4 p. 287-304 Special Invited Article Evasion of host defences by tumours DS Nelson, DS Nelson Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W. 2065 AustraliaSearch for more papers by this authorMargaret Nelson, Margaret Nelson Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W. 2065 AustraliaSearch for more papers by this author DS Nelson, DS Nelson Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W. 2065 AustraliaSearch for more papers by this authorMargaret Nelson, Margaret Nelson Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W. 2065 AustraliaSearch for more papers by this author First published: 01 August 1987 https://doi.org/10.1038/icb.1987.33Citations: 28AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Woglom, WH. 1929. Immunity to transplantable tumors. Cancer Rev. 4: 129–214. 2Foley, EJ. 1953. Antigenic properties of methylcholanthrene induced tumors in mice of the strain of origin. Cancer Res. 13: 835–837. 3Prehn, RT and JM Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Nat. Cancer Inst. 18: 769–778. 4Révész, L. 1960. Detection of antigenic differences in isologous host-tumor systems by pretreatment with heavily irradiated tumor cells. Cancer Res. 20: 443–451. 5Klein, G, HO Sjögren, E Klein and KE Hellström. 1960. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20: 1561–1572. 6Rosenberg, SA, MT Lotze, LM Muul, AE Chang, FP Avis, S Leitman, WM Linehan, CN Robertson, RE Lee, JT Rubin, CA Seipp, CG Simpson and DE White. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316: 889–897. 7Goldstein, D and J Laszio. 1986. Interferon therapy in cancer: From imaginon to interferon. Cancer Res. 46: 4315–4329. 8Herberman, RB and JR Ortaldo. 1981. Natural killer cells: Their role in defenses against disease. Science 214: 24–30. 9Adams, DO and TA Hamilton. 1984. The cell biology of macrophage activation. Ann. Rev. Immunol. 2: 283–318. 10Hewitt, HB, ER Blake and AS Walder. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33: 241–259. 11Baldwin, RW. 1976. Relevant animal models for tumor immunotherapy. Cancer Immunol. Immunother. 1: 197–198. 12Sulitzeanu, D. 1985. Human cancer-associated antigens: Present status and implications for immunodiagnosis. Adv. Cancer Res. 44: 1–42. 13Kearney, R and DS Nelson. 1973. Concomitant immunity to syngeneic methylcholanthrene-induced tumours in mice. Occurrence and specificity of concomitant immunity. Aust. J. Exp. Biol. Med. Sci. 51: 723–735. 14Gorelik, E. 1983. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv. Cancer Res. 39: 71–120. 15Altevogt, P, P Von Hoegen and V Schirrmacher. 1986. Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agents. Int. J. Cancer 38: 707–711. 16Weiss, DW. 1977. The questionable immunogenicity of certain neoplasms. What then the prospects for immunological intervention in malignant disease? Cancer Immunol. Immunother. 2: 11–19. 17Pietersz, GA, J Kanellos, MJ Smyth, J Zalcberg and IFC McKenzie. 1987. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunol. Cell Biol. 65: 111–125. 18Baldwin, RW. 1975. In vitro assays of cell-mediated immunity to human solid tumors: Problems of quantitation, specificity and interpretation. J. Nat. Cancer Inst. 55: 745–748. 19Herberman, RB and RK Oldham. 1975. Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J. Nat. Cancer Inst. 55: 749–753. 20Hollinshead, AC, WT Jaffurs, LK Alpert, JE Harris and RB Herberman. 1974. Isolation and identification of soluble skin-reactive membrane antigens of malignant and normal human breast cells. Cancer Res. 34: 2961–2968. 21Halliday, WJ, TA Koppi, JM Khan and NC Davis. 1980. Leukocyte adherence inhibition: Tumor specificity of cellular and serum-blocking reactions in human melanoma, breast cancer, and colorectal cancer. J. Nat. Cancer Inst. 65: 327–335. 22Hérin, M, C Lemoine, P Weynants, F Vessierè, A Van Pel, A Knuth, R Devos and T Boon. 1987. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 39: 390–396. 23Muul, LM, PJ Spiess, EP Director and SA Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138: 989–995. 24Doherty, PC, BB Knowles and PJ Wettstein. 1984. Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv. Cancer Res. 42: 1–65. 25Momburg, F, T Degener, E Bacchus, G Moldenhauer, GJ Hämmerling and P Möller. 1986. Loss of HLA-A,B,C, and de novo expression of HLA-D in colorectal cancer. Int. J. Cancer 37: 179–184. 26Ghosh, AK, M Moore, AJ Street, JMT Howat and PF Schofield. 1986. Expression of HLA-D subregion products on human colorectal carcinoma. Int. J. Cancer 38: 459–464. 27Van Den Ingh, HF, DJ Ruiter, G Griffioen, GNP Van Muijen and S Ferrone. 1987. HLA antigens in colorectal tumour — low expression of HLA Class I antigens in mucinous colorectal carcinomas. Br. J. Cancer 55: 125–130. 28Heppner, GH. 1984. Tumor heterogeneity. Cancer Res. 44: 2259–2265. 29Woodruff, MFA, JD Ansell, BA Hodson and HS Micklem. 1984. Specificity of tumour associated transplantation antigens (TATA) of different clones from the same tumour. Br. J. Cancer 49: 5–10. 30Guy, K, AS Krajewski and AE Dewar. 1986. Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma. Br. J. Cancer 53: 161–173. 31Gorelik, E. 1987. MHC antigen expression and metastatic properties of tumor cells. In Immune Responses to Metastases, Volume I (R. B. Herberman, R. H. Wiltrout and E. Gorelik eds.), CRC Press, Boca Raton, pp. 35–55. 32Tanaka, K, KJ Isselbacher, G Khoury and G Jay. 1985. Reversal of oncogenesis by the expression of a major histocompatibility complex Class I gene. Science 228: 27–30. 33Taramelli, D, G Fossati, A Mazzocchi, D Delia, S Ferrone and G Parmiani. 1986. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res. 46: 433–439. 34Hui, K, F Grosveld and H Festenstein. 1984. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311: 750–752. 35Hornung, MO, ET Krementz, KA Sullivan, JH Muchmore, I Prats, N Wang and R Strand. 1986. Immunological heterogeneity in human melanoma: immunogenic alloantigen expression in autologous host. Cancer Res. 46: 3704–3710. 36Pfizenmaier, K, P Scheurich, C Schlüter and M Krönke. 1987. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J. Immunol. 138: 975–980. 37Feldman, JD. 1972. Immunologic enhancement: A study of blocking antibodies. Adv. Immunol. 15: 167–214. 38Hellström, KE, I Hellström and JJ Nepom. 1977. Specific blocking factors — are they important? BBA Reviews on Cancer 473: 121–148. 39Noonan, FP and WJ Halliday. 1980. Genetic restriction of the serum factor mediating tolerance in trinitrochlorobenzene hypersensitivity. Cell. Immunol. 50: 41–47. 40Halliday, WJ and AE Maluish. 1982. Hemocytometer LAI: Immunological basis and applications. In Assessment of Immune Status by the Leukocyte Adherence Inhibition Test. D. M. Thomson (ed.), Academic Press, New York, pp. 3–26. 41Baldwin, RW, MR Price and RA Robins. 1972. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nature New Biol. 238: 185–187. 42Robins, RA and RW Baldwin. 1978. Immune complexes in cancer. Cancer Immunol. Immunother. 4: 1–3. 43Halliday, WJ, CL Button, TA Koppi, FP Noonan and IFC McKenzie. 1980. Identification of I-J antigenic determinants on a hapten-specific serum blocking factor. Immunol. Lett. 1: 325–327. 44Koppi, TA and WJ Halliday. 1982. Further characterization of the cells involved in leukocyte adherence inhibition with murine tumor extracts. Cell. Immunol. 66: 394–406. 45Winter, M, DS Nelson and GW Milton. 1980. Leucocyte adherence inhibition test for the detection of cell-mediated immunity to malignant melanoma. Aust. N.Z. J. Med. 10: 405–409. 46Naor, D. 1979. Suppressor Cells: Permitters and promoters of malignancy? Adv. Cancer Res. 29: 45–125. 47Greene, MI. 1980. The genetic and cellular basis of regulation of the immune response to tumor antigens. Contemp. Top. Immunobiol. 11: 81–116. 48Schatten, S, RD Granstein, JA Drebin and MI Greene. 1984. Suppressor T cells and the immune response to tumors. CRC Crit. Rev. Immunol. 4: 335–379. 49North, RJ. 1985. Down-regulation of the antitumor immune response. Adv. Cancer Res.. 45: 1–43. 50North, RJ. 1984. The murine anti-tumor immune response and its therapeutic manipulation. Adv. Immunol. 35: 89–155. 51Nelson, M, DS Nelson, IFC McKenzie and RV Blanden. 1981. Thy and Ly markers on lymphocytes initiating tumor rejection. Cell. Immunol. 60: 34–42. 52Kearney, R, A Basten and DS Nelson. 1975. Cellular basis of the immune response to methylcholanthrene-induced tumours in mice. Heterogeneity of effector cells. Int. J. Cancer 15: 438–450. 53Haubeck, H-D and E Kölsch. 1982. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in Balb/c mice III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis. Immunology 47: 503–510. 54Kölsch, E, R Mengersen and E Diller. 1973. Low zone tolerance preventing tumor immunity. Eur. J. Cancer 9: 879–882. 55Gatenby, PA, A Basten and P Creswick. 1981. 'Sneaking through': A T-cell-dependent phenomenon. Br. J. Cancer 44: 753–756. 56McBride, WH and SEM Howie. 1986. Induction of tolerance to a murine fibrosarcoma in two zones of dosage — the involvement of suppressor cells. Br. J. Cancer 53: 707–711. 57Kripke, ML. 1981. Immunologic mechanisms in UV radiation carcinogenesis. Adv. Cancer Res. 34: 69–106. 58Bear, HD. 1986. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens. Cancer Res. 46: 1805–1812. 59Levy, JG, T Maier and DG Kilburn. 1979. Further characterization of thymic suppressor cells and a factor that suppresses the generation of cells cytotoxic for a syngeneic tumor in DBA/2 mice. J. Immunol. 122: 766–771. 60Steele, JK, R Singhai, AT Stammers and JG Levy. 1986. Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210. J. Immunol. 137: 3025–3030. 61Mukherji, B, SA Wilhelm, A Guha and MT Ergin. 1986. Regulation of cellular immune response against autologous human melanoma I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J. Immunol. 136: 1888–1892. 62Mukherji, B, AL Nashad, A Guha and MT Ergin. 1986. Regulation of cellular immune response against autologous human melanoma II. Mechanism of induction and specificity of suppression. J. Immunol. 136: 1893–1898. 63Nelson, DS. 1976. Non-specific immunoregulation by products of macrophages and other cells. In Immunobiology of the Macrophage. D. S. Nelson (ed.), Academic Press, New York, pp, 235–257. 64Varesio, L. 1983. Suppressor cells and cancer: Inhibition of immune functions by macrophages. In The Reticuloendothelial System. A Comprehensive Treatise. Vol. 5, Cancer. R. B. Herberman and H. Friedman (eds.), Plenum Press, New York, pp. 217–252. 65Nelson, DS. 1987. Alterations in macrophage function in tumor-bearing hosts. In Immune Responses to Metastases, Vol. I. R. B. Herberman, R. H. Wiltrout and E. Gorelik (eds.), CRC Press, Boca Raton, pp. 79–103. 66Cheers, C, H Pavlov, C Riglar and E Madrasso. 1980. Macrophage activation during experimental murine brucellosis III. Do macrophages exert feedback control during brucellosis? Cell. Immunol. 49: 168–177. 67Fujii, TT Igarashi and S Kishimoto. 1987. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice. J. Nat. Cancer Inst. 78: 509–517. 68Young, MR and M Newby. 1986. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice. Cancer Res. 77: 1255–1260. 69Gerson, JM, L Varesio and RB Herberman. 1981. Systemic and in situ natural killer and suppressor cell activities in mice bearing progressively growing murine sarcoma-virus-induced tumors. Int. J. Cancer 27: 243–248. 70Young, MR and CS Hoover. 1986. Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma. J. Nat. Cancer Inst. 77: 425–429. 71Kedar, E, A Katz-Gross, E Chriqui-Zeira and H Bercowitz. 1984. Suppression by tumor growth of T cell growth factor production in mouse lymphoid cell cultures. J. Biol. Response Mod. 3: 547–560. 72Goodwin, JS, RP Messner, AD Bankhurst, GT Peake, JH Saiki and RC Williams. 1977. Prostaglandin-producing suppressor cells in Hodgkin's disease. N. Engl. J. Med. 297: 963–968. 73Santos, LB, FT Yamada and MA Scheinberg. 1985. Monocyte and lymphocyte interaction in patients with advanced cancer. Cancer 56: 1553–1558. 74Bjercke, S, M Onsrud and G Gaudernack. 1986. Suppressive effect of monocytes in vitro in patients with carcinoma of the uterine cervix. Acta Obstet. Gynecol. Scand. 65: 619–624. 75Braun, DP and JE Harris. 1986. Abnormal monocyte function in patients with Kaposi's sarcoma. Cancer 57: 1501–1506. 76Small, M. 1982. Tumor enhancing T lymphocytes in mice: Further studies on characteristics and mechanism of activity. Int. J. Cancer 29: 465–469. 77Hellström, KE and I Hellström. 1981. Cell-mediated suppression of tumor immunity has a nonspecific component. I. Evidence from transplantation tests. Int. J. Cancer 27: 481–485. 78Hellström, I and KE Helström. 1981. Cell-mediated suppression of tumor immunity has a nonspecific component II, Evidence from cell culture experiments. Int. J. Cancer 27: 487–491. 79Werkmeister, J, W McCarthy and P Hersey. 1981. Suppressor cell activity in melanoma patients, I. Relation to tumor growth and immunoglobulin levels in vivo. Int. J. Cancer 28: 1–9. 80Werkmeister, J, G Phillips, W McCarthy and P Hersey. 1981. Suppressor cell activity in melanoma patients. II. Concanavalin A-induced suppressor cells in relation to tumor growth and suppressor T-cell subsets. Int. J. Cancer 28: 11–15. 81Koyama, S, K Fukao and S Fujimoto. 1985. The generation of interleukin-2-dependent suppressor T-cells from patients with systemic metastasis of gastric carcinoma and the phenotypic characterization of cells defined by monoclonal antibodies. Cancer 56: 2437–2445. 82Hoon, DSB, RJ Bowker and AJ Cochran. 1987. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res. 47: 1529–1533. 83Asherson, GL, V Colizzi and M Zembala. 1986. An overview of T-suppressor cell circuits. Ann. Rev. Immunol. 4: 37–68. 84Ramila, G and P Erb. 1983. Accessory cell-dependent selection of specific T-cell functions. Nature 304: 442–445. 85Malkovsky, M and PB Medawar. 1984. Is immunological tolerance (non-responsiveness) a consequence of interleukin 2 deficit during the recognition of antigen? Immunol. Today 5: 340–343. 86Burger, CJ, KD Elgert and WL Farrar. 1984. Interleukin 2 (IL-2) activity during tumor growth: IL-2 production kinetics, absorption of and responses to exogenous IL-2. Cell. Immunol. 84: 228–239. 87Ting, C-C and D Rodrigues. 1980. Immunoregulatory circuit among macrophage subsets for T cell-mediated cytotoxicity response to tumor cells. J. Immunol. 124: 1039–1044. 88Young, MR, M Newby and TH Wepsic. 1987. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 47: 100–105. 89Nelson, DS, M Nelson, E Farram and Y Inoue. 1981. Cancer and subversion of host defences. Aust. J. Exp. Biol. Med. Sci. 59: 229–262. 90Levy, MH and EF Wheelock. 1974. The role of macrophages in defence against neoplastic disease. Adv. Cancer Res. 20: 131–163. 91Kamo, I and H Friedman. 1977. Immunosuppression and the role of suppressive factors in cancer. Adv. Cancer Res. 25: 271–321. 92North, RJ, GL Spitalny and DP Kirstein. 1978. Anti-tumor defense mechanisms and their subversion. In The Handbook of Cancer Immunology, Vol. 2, Cellular Escape from Immune Destruction. H. Waters (ed.), Garland STPM Press, New York, pp. 187–223. 93Stern, K. 1983. Control of tumors by the RES. In The Reticuloendothelial System. A Comprehensive Treatise. Vol. 5, Cancer. R. B. Herberman and H. Friedman (eds.), Plenum Press, New York, pp. 59–153. 94Cianciolo, GJ and R Snyderman. 1983. Neoplasia and mononuclear phagocyte function. In The Reticuloendothelial System. A Comprehensive Treatise. Vol. 5, Cancer. R. B. Herberman and H. Friedman (eds.), Plenum Press, New York, pp. 193–216. 95Normann, SJ. 1985. Macrophage infiltration and tumor progression. Cancer Metast. Rev. 4: 277–291. 96Pross, HF and MG Baines. 1987. Alterations in natural killer cell activity in tumor-bearing hosts. In Immune Responses to Metastases, Vol. I. R. B. Herberman, R. H. Wiltrout and E. Gorelik (eds.), CRC Press, Boca Raton, pp. 57–78. 97Farram, E, M Nelson and DS Nelson. 1981. Macrophages and resistance to tumors V. The effects of tumor cell products on monocytopoiesis. J. Reticuloendothelial. Soc. 30: 259–269. 98Goodwin, JS, G Husby and RC Williams Jr. 1980. Prostaglandin E and cancer growth. Cancer Immunol. Immunother. 8: 3–7. 99Cooperband, SR, R Nimberg, K Schmid and JA Mannik. 1976. Humoral immunosuppressive factors. Transplant. Proc. 8: 225–242. 100Boetcher, DA and EJ Leonard. 1974. Abnormal monocyte chemotactic response in cancer patients. J. Nat. Cancer Inst. 52: 1091–1094. 101Snyderman, R, HF Seigler and L Meadows. 1977. Abnormalities of monocyte chemotaxis in patients with melanoma: Effects of immunotherapy and tumor removal. J. Nat. Cancer Inst. 58: 37–41. 102Al-Sumidaie, AM, GP Copeland, SJ Leinster and SA Jenkins. 1986. The effect of colorectal malignancies on monocyte migration, lysozyme production, and phagocytosis. Eur. J. Surg. Oncol. 12: 367–371. 103Walter, RJ, JR Danielson, PJ Van Alten and WJ Powell. 1986. Defects in monocyte chemotaxis in patients with neoplastic disease. J. Surg. Res. 41: 215–224. 104Mantovani, A, TR Jerrells, JH Dean and RB Herberman. 1979. Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int. J. Cancer 23: 18–27. 105Haskill, JS, JW Proctor and Y Yamamura. 1975. Host responses within solid tumors. I. Monocytic effector cells within rat sarcomas. J. Nat. Cancer Inst. 54: 387–393. 106Vose, BM. 1978. Cytotoxicity of adherent cells associated with some human tumours and lung tissues. Cancer Immunol. Immunother. 5: 173–179. 107Takeo, S, K Yasumoto, A Nagashima, H Nakahashi, K Sugimachi and K Nomoto. 1986. Role of tumor-associated macrophages in lung cancer. Cancer Res. 46: 3179–3182. 108Steele, RJC, O Eremin and M Brown. 1983. Blood monocytes and tumor-infiltrating macrophages in human breast cancer: Differences in activation level as assessed by lysozyme content. J. Nat. Cancer Inst. 71: 941–945. 109Evans, R. 1979. Host cells in transplanted murine tumors and their possible relevance to tumor growth. J. Reticuloendothel. Soc. 26: 427–437. 110Nash, JRG, JE Price and D Tarin. 1981. Macrophage content and colony-forming potential in mouse mammary carcinomas. Br. J. Cancer 39: 478–485. 111Key, M, JE Talmadge and IJ Fidler. 1982. Lack of correlation between the progressive growth of spontaneous metastases and their content of infiltrating macrophages. J. Reticuloendothel. Soc. 32: 387–396. 112Steele, RJC, O Eremin, M Brown and RA Hawkins. 1984. A high macrophage content in human breast cancer is not associated with favourable prognostic factors. Br. J. Surg. 71: 456–458. 113Loveless, SE, GH Heppner. 1983. Tumor-associated macrophages of mouse mammary tumors I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors. J. Immunol. 131: 2074–2078. 114North, SM and GL Nicolson. 1987. Host responses and tumor metastasis. In Immune Responses to Metastases, Vol. I. R. B. Herberman, R. H. Wiltrout and E. Gorelik (eds.), CRC Press, Boca Raton, pp. 1–22. 115Mantovani, A, B Bottazzi, P Allavena and B Balotta. 1987. Tumor-associated leukocytes in metastasizing tumors. In Immune Responses to Metastases, Vol. I. R. B. Herberman, R. H. Wiltrout and E. Gorelik (eds.), CRC Press, Boca Raton, pp. 105–118. 116Allen, C and N Hogg. 1987. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J. Nat. Cancer Inst. 78: 465–470. 117Moy, PM, EC Holmes and SH Golub. 1985. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. 45: 57–60. 118Schantz, SP, EJ Shillitoe, B Brown and B Campbell. 1986. Natural killer cell activity and head and neck cancer: a clinical assessment. J. Nat. Cancer Inst. 77: 869–875. 119Snyderman, R and GJ Cianciolo. 1984. Immunosuppressive activity of the retroviral envelope protein p15E and its possible relationship to neoplasia. Immunol. Today 5: 240–244. 120Normann, SJ. 1988. Modulation of natural immunity by local tissue injury. In Natural Immunity. D. S. Nelson (ed.), Academic Press, Sydney, in the press. 121Nelson, M and DS Nelson. 1978. Macrophages and resistance to tumours I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble products affecting macrophages. Immunology 34: 277–290. 122Nelson, M and DS Nelson. 1980. Macrophages and resistance to tumor IV. Influence of age on susceptibility of mice to anti-inflammatory and antimacrophage effects of tumor cell products. J. Nat. Cancer. Inst. 65: 781–789. 123Nelson, M and DS Nelson. 1982. Macrophages and resistance to tumors 6. The effects of supernatants from cultures of normal and tumor cells on phagocytosis. J. Reticuloendothel. Soc. 31: 433–450. 124Nelson, M, ML Booth and DS Nelson. 1982. Effects of tumour cell culture supernatants on some biochemical activities of macrophages. Aust. J. Exp. Biol. Med. Sci. 60: 493–502. 125Riley, V, DH Spackman, GA Santisteban, G Dalldorf, I Hellström, KE Hellstöm, EM Lance, KEK Rowson, BWJ Mahy, P Alexander, CC Stock, HO Sjögren, VP Hollander and MC Horzinek. 1978. The LDH virus: An interfering biological contaminant. Science 200: 124–126. 126Cole, BC, GJ Sullivan, RA Daynes, IA Sayed and JR Ward. 1982. Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis II, Cellular requirements for T cell transformation mediated by a soluble mycoplasma mitogen. J. Immunol. 128: 2013–2018. 127Jakway, JP and EM Shevach. 1984. Mycoplasma contamination: a hazard of screening hybridoma supernatants for inhibition of (3H) thymidine incorporation. J. Immunol. Meth. 67: 337–345. 128Hersh, EM and B Drewinko. 1974. Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res. 34: 215–220. 129Werkmeister, J, J Zaunders, W McCarthy and P Hersey. 1980. Characterization of an inhibitor of cell division released in tumour cell cultures. Clin. Exp. Immunol. 41: 487–496. 130Whitehead, JS and YS Kim. 1980. An inhibitor of lymphocyte proliferation produced by a human colonic adenocarcinoma cell line in culture. Cancer Res. 40: 29–35. 131Renk, CM, RK Gupta and DL Morton. 1980. Immunosuppressive factors from human breast carcinoma cell lines that affect initiation of lymphocyte proliferation. Cancer Immunol. Immunother. 9: 55–62. 132Roth, JA, EA Grimm, RK Gupta and RS Ames. 1982. Immunoregulatory factors derived from human tumors I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J. Immunol. 128: 1955–1962. 133McCabe, M, M Nowak, D Maguire and P Robertson. 1984. Immunosuppression by human skin cancers. Aust. J. Exp. Biol. Med. Sci. 62: 539–545. 134San Marco, MP, GJ Pommier, MC Chabrol, DH Adda and RC Depieds. 1984. Immunomodulating activities associated with the cytosol fraction of a 3-methylcholanthrene-induced rat fibrosarcoma. J. Nat. Cancer Inst. 72: 1101–1111. 135Miescher, S, TL Whiteside, S Carrel and V Von Fliedner. 1986. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136: 1899–1907. 136Walsh, JD, Arid CL Geczy. 1982. Inhibition of the lymphocyte blastogenic response to antigen by serum-free culture supernatants of leukamic B cells. Cell. Immunol. 67: 241–254. 137Blazar, BA, LM Sutton and M Strome. 1986. Immunomodulating activity in supernatants from EBV immortalized lymphocytes. Cancer Immunol. Immunother. 22: 62–67. 138Fujiwara, H, Z Toossi, K Ohnishi, K Edmonds and JJ Ellner. 1987. Spontaneous production of a suppressor factor by a human macrophage-like cell line, II. Suppression of antigen- and mitogen-induced blastogenesis, IL2 production and IL2 receptor expression in T lymphocytes. J. Immunol. 138: 197–203. 139Farram, E, M Nelson, DS Nelson and DK Moon. 1982. Inhibition of cytokine production by a tumour cell product. Immunology 46: 603–612. 140Herman, J, MC Kew and AR Rabson. 1984. Defective IL-1 production by monocytes from patients with malignant disease. Cancer Immunol. Immunother. 16: 182–185. 141Herman, J, MC Kew and AR Rabson. 1985. Defective interleukin-1 production by natural killer cells of patients with cancer. Cancer Immunol. Immunother. 19: 148–153. 142Ravikumar, T, M Rodrick, G Steele Jr, J Marrazzo, P O'Dwyer, T Dodson and V King. 1985. Interleukin generation in experimental colon cancer of rats: Effects of tumor growth and tumor therapy. J. Nat. Cancer Inst. 74: 893–898. 143Lyte, M and PH Bick. 1986. Modulation of interleukin-1 production by macrophages following benzo(a)pyrene exposure. Int. J. Immunopharmacol. 8: 377–381. 144Szuro-Sudol, A, HW Murray and CF Nathan. 1983. Suppression of macrophage antimicrobial activity by a tumor cell product. J. Immunol. 131: 384–387. 145Tsunuwaki, S and CF Nathan. 1986. Macrophage deactivation. Altered kinetic properties of superoxide-producing enzyme after exposure to tumor cell-conditioned medium. J. Exp. Med. 164: 1319–1331. 146Nakamura, K, Y Nakajima and Y Nakamura. 1986. Suppression of glucose utilization of murine peritoneal exudate macrophages by body fluids from cancer patients and identification of the susceptible enzyme. J. Nat. Cancer Inst. 77: 1035–